An investor, who purchased NASDAQ:ELGX shares, filed a lawsuit against Endologix, Inc over alleged violations of Federal Securities Laws.
Investors who purchased shares of Endologix, Inc. (NASDAQ:ELGX) have certain options and for certain investors are short and strict deadlines running. Deadline: March 6, 2017. NASDAQ:ELGX investors should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 – 1554.
The plaintiff alleges on behalf of purchasers of Endologix, Inc. (NASDAQ:ELGX) common shares between August 2, 2016 and November 16, 2016, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between August 2, 2016 and November 16, 2016 the Defendants made false and/or misleading statements and/or failed to disclose that Endologix did not have the requisite clinical data for FDA premarket approval of its Nellix® EndoVascular Aneurysm Sealing System, and that as a result, Endologix’s public statements were materially false and misleading at all relevant times.
On August 2, 2016, CEO John McDermott indicated that Endologix, Inc would seek approval of the original version of the Nellix system that was used in the Nellix investigational device exemption (IDE) clinical trial, the EVAS FORWARD-IDE Study, given that Endologix, Inc had the needed clinical data.
On November 16, 2016, Endologix, Inc announced that the FDA has requested two-year follow-up data on patients enrolled in the EVAS-FORWARD-IDE study to assess Nellix. Shares of Endologix, Inc. (NASDAQ:ELGX) declined to as low as $6.22 per share on November 16, 2016.
On December 27, 2016, Endologix, Inc announced a temporary hold on shipments of its AFX® Endovascular AAA System to complete an investigation of a manufacturing issue with some sizes of the device. Shares of Endologix, Inc. (NASDAQ:ELGX) declined to as low as $4.78 per share on December 28, 2016.
On January 13, 2017, NASDAQ:ELGX shares closed at $6.49 per share.
Those who purchased NASDAQ:ELGX shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego